Agios Pharmaceuticals, Inc. stock plunged 49% after mixed Phase 3 results for mitapivat in Sickle Cell Disease, raising doubts about future approvals. Mitapivat met the primary hemoglobin endpoint but ...

Around a fifth of solar panels examined in a new study fail much faster than expected and some may last for only half their anticipated lifetime. New research has uncovered a critical challenge in ...